chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I had slight chills & fevers for 2 days after both injections of Moderna Vax.   What concerns me, however, is that since the 2nd vax I have had what I describe as electric or fizzing sensations anywhere on my body - legs, arms, torso, head - on and off, all day long, every day.    Today I read an article by Dr, "What is the Corona Virus Fizzing Symptom?"   It relates similar symptoms by patients who had the virus.   It was the first time I felt that perhaps this might be a side effect of the vax too.   The underlined words ("electric feeling") were referenced by other covid patients on Twitter who complained of the same sensations
This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 45-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 13Dec2021 as dose 3 (booster), single (Lot number: FD7218) at the age of 45 years, in left arm for Covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. Vaccination history included: BNT162b2 (Dose Number: 2, Batch/Lot No: EW0173, Location of injection: Arm Left), administration date: 30Apr2021, when the patient was 44-year-old, for Covid-19 Immunization; Pfizer (Dose Number: 1, Batch/Lot No: FW0158, Location of injection: Arm Left), administration date: 09Apr2021, when the patient was 44-year-old, for Covid-19 Immunization. The following information was reported: PEMPHIGOID (medically significant) with onset 01Jan2022, outcome "not recovered", described as "Bullous pemphigoid"; MENSTRUATION IRREGULAR (non-serious) with onset 01Jan2022, outcome "not recovered", described as "Very first month after 3shot - my period changed"; VISUAL IMPAIRMENT (non-serious) with onset 01Jan2022, outcome "not recovered", described as "eye sight changed". The events "bullous pemphigoid", "very first month after 3shot - my period changed" and "eye sight changed" required physician office visit. The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Unknown results. Therapeutic measures were taken as a result of pemphigoid, menstruation irregular, visual impairment. Additional information: The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not receive any other medications within 2 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has been tested for COVID-19. Reported Event: Very first month after 3shot - my period changed and eye sight changed. Now my doctor diagnosed Bullous pemphigoid. No follow-up attempts are possible. No further information is expected.
Expired vaccine used; Product administration error; This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and PRODUCT ADMINISTRATION ERROR (Product administration error) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Oct-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and PRODUCT ADMINISTRATION ERROR (Product administration error). On 08-Oct-2021, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and PRODUCT ADMINISTRATION ERROR (Product administration error) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications reported by reporter No treatment medications provided by the reporter.
No Adverse event; Patient was administered Moderna COVID-19 vaccine for 6-11 years, instead of the bivalent Moderna booster; This spontaneous case was reported by a pharmacist and describes the occurrence of WRONG PRODUCT ADMINISTERED (Patient was administered Moderna COVID-19 vaccine for 6-11 years, instead of the bivalent Moderna booster) and NO ADVERSE EVENT (No Adverse event) in a 30-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 064A22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 27-Sep-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 27-Sep-2022, the patient experienced WRONG PRODUCT ADMINISTERED (Patient was administered Moderna COVID-19 vaccine for 6-11 years, instead of the bivalent Moderna booster). On an unknown date, the patient experienced NO ADVERSE EVENT (No Adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Patient was administered Moderna COVID-19 vaccine for 6-11 years, instead of the bivalent Moderna booster) and NO ADVERSE EVENT (No Adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No Adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (Patient was administered Moderna COVID-19 vaccine for 6-11 years, instead of the bivalent Moderna booster).    No concomitant medications were reported. The patient had not reported an adverse reactions. No treatment information was provided.
This spontaneous report as received from a register nurse refers to an unspecified number of patients of unknown age. No concomitant medication, pertinent medical history, drug reactions or allergies were reported. In 2014 (exact date unspecified) the unspecified number of patients were administered doses of RECOMBIVAX HB 10 microgram/ml (lot #, expiration date, strength, dose and frequency were not reported) that were improperly stored. Doses of this vaccines were administered after 23-JAN-2014 until an unspecified date (date approximated: 2014). No adverse events were reported. This is several reports from the same source (MARRS # 1404USA015276, 1404USA15277). Additional information has been requested.
From the time the second vaccine was administered until today (April 7, 2022), I am still dealing with intense hives, rashes, and bodily discomfort. I break out in hives randomly throughout the day, often covering large surface areas which take anywhere from 1-3 hours to normalize. The hives are extremely itchy and hard to ignore. Oftentimes, I wake up with lips and ears swollen which is a sign that there will be more breakouts in the near future. At times, my throat closes up and it becomes difficult to breathe.
Information has been received from a medical assistant referring to an unspecified number of patients of unknown age and gender. The patients' medical history and concurrent conditions were not reported. Concomitant therapies included sterile diluent (manufacturer unknown). On 01-SEP-2017, the patients were vaccinated with improperly stored VARIVAX (dose, frequency and route were unknown, lot # M049127, expiration date: 15-DEC-2018, lot # N010107, expiration date: 28-MAR-2019) for prophylaxis. Administered vaccine experienced the temperature excursion of -14 Celsius degree to -10 Celsius degree (-14.2 Celsius degree) for 6 hours. There was no previous temperature excursion. Data logger was involved. No adverse effects reported. No product quality complaint (PQC) was involved. This is one of several reports from the same reporter. All telephone attempts on 10-OCT-2017 to obtain follow up information have been unsuccessful. Follow up information has been received from an other reporter concerning a 12 month old patient. On 11-SEP-2017, the patient vaccinated with improperly stored VARIVAX (dose, frequency and route were unknown, lot # M049127, expiration date: 15-DEC-2018) for prophylaxis. This is one of several reports from the same reporter. Sender's Comments: US-009507513-1709USA002098: US-009507513-1709USA002186.
ITP - Immune Thrombotic Purpura leading to intercerebral hemorrhage
WEAKNESS; UNABLE TO BALANCE; DIARRHEA; FOGGY FEELING IN HEAD; CONCENTRATION IMPAIRED; DIZZINESS; EXHAUSTED; FEVER; NAUSEA; SWEATS; VOMITED; BODY ACHES; IMPAIRED DRIVING ABILITY; CHILLS; SORE ARM; This spontaneous report received from a patient concerned a 52 year old female. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 042A21A, and expiry: UNKNOWN) dose was not reported, administered on 06-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 06-APR-2021, the subject experienced sweats. On 06-APR-2021, the subject experienced vomited. On 06-APR-2021, the subject experienced body aches. On 06-APR-2021, the subject experienced impaired driving ability. On 06-APR-2021, the subject experienced chills. On 06-APR-2021, the subject experienced sore arm. On 06-APR-2021, the subject experienced fever. On 06-APR-2021, the subject experienced nausea. On 07-APR-2021, the subject experienced dizziness. On 07-APR-2021, the subject experienced exhausted. On 08-APR-2021, the subject experienced concentration impaired. On 09-APR-2021, the subject experienced diarrhea. On 09-APR-2021, the subject experienced foggy feeling in head. On 10-APR-2021, the subject experienced unable to balance. On 11-APR-2021, the subject experienced weakness. Laboratory data (dates unspecified) included: Blood test (NR: not provided) No Blood clots, Normal platelets, CT scan (NR: not provided) waiting to get it done, and Coronavirus test (NR: not provided) Negative. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from sweats, diarrhea, and nausea on 10-APR-2021, vomited on 07-APR-2021, body aches on 13-APR-2021, chills, and fever on 08-APR-2021, and sore arm, was recovering from dizziness, and had not recovered from exhausted, concentration impaired, weakness, foggy feeling in head, impaired driving ability, and unable to balance. This report was non-serious.
Rash; Itching; This is a spontaneous report from a contactable consumer (patient). A 50-year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 1 via an unspecified route of administration, administered in the right arm on 27Feb2021 at 11:30 (lot number: EN6202) at a single dose, received at the  Clinic Administration facility for covid-19 immunisation.  Medical history included was reported as none. The patient had no COVID prior to vaccination. The patient's concomitant medications were not reported. The patient experienced rash and itching on 04Mar2021. They didn't notice right away though. Symptoms started 5 days after injection. It was unknown if the patient received treatment for the events. The events resulted in emergency room/department or urgent care visit. The patient was not tested for COVID post vaccination. Outcome of the events was unknown.
full body red rash; full body red rash; slight shortness of breath; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient.  A 48 year-old male patient received bnt162b2 (BNT162B2), administered in arm right, administration date 26Dec2020 (Lot number: EL1284) at the age of 48 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Known allergy-carrot" (unspecified if ongoing); "Known allergy-penicillin" (unspecified if ongoing). The patient took concomitant medications. Past drug history included: Morphine, reaction(s): "known allergies : morphine". The following information was reported: RASH ERYTHEMATOUS (non-serious), RASH (non-serious), outcome "unknown" and all described as "full body red rash"; DYSPNOEA (non-serious), outcome "unknown", described as "slight shortness of breath". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: Patient experienced full body red rash with slight shortness of breath on first dose, when I got the 2nd dose a month later, he took 1000mg Tylenol, and 50 mg Benadryl 1 hour prior to vaccine and still ended up with body rash and shortness of breath. both time this was with in less than 5 minutes of getting the Pfizer vaccine.  No follow-up attempts are possible. No further information is expected.
Complained of itchy bloodshot eyes 2 hours after vaccine administration. Had symptoms throughout evening. Next morning, symptoms were resolved.
injection site pain almost immediately; headache; fever; This case was reported by a consumer  and described the occurrence of injection site pain in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 7th December 2020, the patient received the 2nd dose of Shingrix. On 7th December 2020, immediately after receiving Shingrix, the patient experienced injection site pain, headache and fever. On an unknown date, the outcome of the injection site pain, headache and fever were not recovered/not resolved.   It was unknown if the reporter considered the injection site pain, headache and fever to be related to Shingrix.  Additional details were provided as follows: The case was reported by the wife of the patient. The age at the vaccination was not reported. The patient received Shingrix and had injection site arm pain almost immediately. The patient developed headache and fever as well and that these symptoms persist. The reporter did not had vaccine information for this adverse event and declined follow up. The reporter did not consent to follow up. This case linked with US2020243295, reporter by same reporter for patient wife.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020243295:Same Reporter
Headache, body ache, temperture of 104, lost of appitite, stomach pain, eyes hurt.
Patient had a syncopal event post vaccination resulting a fall to the floor with hitting his head.  Patient quickly regained consciousness.  911 was contacted and came to look  over the patient.  It was determined that emergency medical treatment was not needed and hospitalization not necessary.
He started out with sneezing and cough and mucus production. Some difficulty breathing and a fever. That fever continued nearly every day until a few days ago. He did develop high fevers a couple times. He was almost taken to the emergency room. He developed a full body rash that came and went a few times over the last few weeks. He developed vomiting last week. He was lethargic, loss of appetite, and some general pain. He developed a mouth sore and respiratory distress at some point that required a nebulizer. He's been sick for the last month basically. He was just taking children's Tylenol. He was also given a course of Amoxicillin for 10 days with no effect. He was also put on Fluticasone, Hydrocortisone, and Triamcinolone. At some point, he also developed a severe sore throat and lost his voice. He was seen at an urgent care on 06/29/2022 and that was the first time we went. Total, there were 2 urgent care visits and 3 office visits.
1st dose before Covid and never came back for the 2nd dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in an unspecified number of patients who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (on an unknown date the several patients received 1st dose,).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: 1st dose before Covid and never came back for the 2nd dose).  The outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 31-AUG-2023 The pharmacist had an inquiry on restarting the series or not for patients who got 1st dose and missed the 2nd dose of Shingrix.  He had several patients inquiring since they got the 1st dose before Covid and never came back for the 2nd dose. The health care professional did not provide other details. Till the time of reporting the several patient did not received the 2nd dose, which led to incomplete course of vaccination. The HCP did not consent to follow-up.
Moderna COVID?19 Vaccine EUA Vaccine given to pt at 16 years of age. Pt had already received first dose one month prior, and was counseled re use of vaccine outside of approved age range but within reccomendations of CDC for pt already having received first dose.
Vials were reconstituted with only 0.8 mL of NS and three doses drawn from each vial, as opposed to the correct use of 1.8 mL of NS as the diluent.  Patient who received this incorrect dose did not experience any side effects
PNEUMOVAX vaccine became very ill, loss of appetite, chills ability to care for self. Severe diarrhea these symptoms continued through Thanksgiving.
Information has been received from a registered nurse concerning a 11 year old female with no drug reactions/allergies who on 07-JUL-1999 was vaccinated with a dose of varicella virus vaccine live (Oka/Merck). On 02-MAR-2007 the patient developed chicken pox on her face and upper body. The patient sought unspecified medical attention. No diagnostic laboratory tests were performed. The patient was reported to be recovering. There was no product quality complaint. Additional information has been requested. Follow-up received 05/23/2008. Follow-up information received from the physician indicating that on 07-Jul-1999, concomitant therapy included measles-mumps-rubella vaccine (MSD), diphtheria toxoid (-) pertussis acellular vaccine (unspecified) (+) tetanus toxoid and poliovirus vaccine. On 03-Mar-2007. Previously reported on 02-Mar-2007) there was a pruritic rash on the face and upper body, afebrile, 1 day duration. Patient recovered from the events on 05-Mar-2007. No further information is expected. Information has been received from a physician concerinng a 11 year old female who on 07-July-1999 was vaccinated with varicella virus vaccine live (Oka/Merck). On 03-Mar-2007 the patient recovered experienced chicken pox on her face and upper body. Subsequently, the patient recovered from chickenpox on her face and upper body.
WAS UNCONSCIOUS FOR A COUPLE MINUTES; SLUMPED IN HIS CHAIR/FELL ON THE FLOOR; HIT HIS HEAD; EYES ROLLED TO THE BACK OF HIS HEAD; This spontaneous report received from a parent concerned a 27 year old male. The patient's weight, height, and medical history were not reported.  The patient received Covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose was not reported, administered on 14-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 14-MAR-2021, in afternoon and within 3 minutes after vaccination the patient experienced slumped in his chair/fell on the floor, eyes rolled to the back of his head, hit his head, and was unconscious for a couple minutes. The clinicians observed the patient for about 15 additional minutes and sent the patient on his way. The action taken with COVID-19 VACCINE AD26.COV2.S was not applicable. The outcome of the hit his head, eyes rolled to the back of his head, was unconscious for a couple minutes and slumped in his chair/fell on the floor was not reported. The reporter causality between COVID-19 VACCINE AD26.COV2.S and slumped in his chair/fell on the floor, eyes rolled to the back of his head, hit his head and was unconscious for a couple minutes was possible. The company causality between COVID-19 VACCINE AD26.COV2.S and slumped in his chair/fell on the floor, eyes rolled to the back of his head, hit his head and was unconscious for a couple minutes was possible. This report was serious (Other Medically Important Condition).; Sender's Comments: V0: 20210327022-unconscious for couple minutes. This event is considered unassessable. The event has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event.
PT. REPORTED NUMBNESS AND TINGLING TO HER TONGUE AT 10:30, STATED SHE HAD SIMILAR REACTIONS TO SHELLFISH. ADMINISTERED PO BENADRYL AT 1039, SYMPTOMS RESOLVED AT 1106
MEMBER BROKE IN RASH FROM NECK DOWN AFTER 3RD ANTHRAX SHOT
almost passed out this morning, claims to have dizziness.; Very fatigued after the second dose; Headache after second dose; Muscle pain after 2nd dose; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (Very fatigued after the second dose), HEADACHE (Headache after second dose), MYALGIA (Muscle pain after 2nd dose) and DIZZINESS (Dizziness after 2nd dose) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031l20a) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Mar-2021, the patient experienced FATIGUE (Very fatigued after the second dose), HEADACHE (Headache after second dose) and MYALGIA (Muscle pain after 2nd dose). On 10-Mar-2021, the patient experienced DIZZINESS (Dizziness after 2nd dose). The patient was treated with IBUPROFEN at an unspecified dose and frequency and ACETAMINOPHEN at an unspecified dose and frequency. At the time of the report, FATIGUE (Very fatigued after the second dose), HEADACHE (Headache after second dose), MYALGIA (Muscle pain after 2nd dose) and DIZZINESS (Dizziness after 2nd dose) outcome was unknown.
Headache starting about 12 hours after dose; extreme pain at injection site, feverish, sweats, chills, achy muscles and joints,  fatigue/nausea all day today
Pt. experienced dizziness, nausea, vomiting x1 and pallor. Encouraged pt. to take deep breaths, lay head down, took B/P and stayed with pt. for duration.
Pfizer Dose 1 administered.  "Covid Arm" occurred in the arm where vaccinated was received.  Severe rash, burning, swelling occurred for a period of about a week.
Pt vacc. /w DTP/OPV persistent high pitched crying x 8 hrs /p shot given. Fever 102 lasting 18 hrs. No seizures.
1 week after first Moderna covid 19 dose she had sudden onset of shortness of breath and subsequently some chest pain,  She was seen in ER, had elevated D dimer. She had negative CTA for pulmonary embolism and negative cardiac workup that included ekg and cardiac enzymes.  She was dishcharged home and returned in 2 days with similar symptoms and no cause found . She has had recurrent chest heaviness lasting about 1 hour episodically since that time, about 3 times, and has cardiology follow up scheduled.
10/21 22:00:  Nausea, chills (temperature 100) achy; 10/22 afternoon: Red blotched-lower arm; 10/23 9:00:  large swollen area (size of orange), 5 inch below injection site, hot, red, itchy.  Limited mobility elbow; 10/20 PM: saw MD, started on Antibiotics, Motrin, Claritin and Codeine for pain.
Approx 5 hrs p/vax pt had abd cramping, then nausea, vomiting, diarrhea; moderate severity; on 12JUN & 13JUN sl diarrhea cont, some nausea; by 14JUN no s&s no tx;
pt recv vax 3JUN96 & approx 24JUN96 pt exp joint achiness;sx cont;
During the night I started to get achy. By morning, I was hot, then cold all day long. nausea. severe muscle aches, skin hurt, hurt to breathe because my ribcage hurt. severe pain in neck and spine. Fatigue. Arm pain from the injection. I took Advil and it helped but I had to take it every 3 hours during the day. When the Advil wore off, the symptoms returned.
within the hour - injection site became itchy. Noticed it was red, swollen, very tender, itchy and hot to the touch. Called the pharmacists who encouraged I take a Benadryl which helped the rest of the day with symptoms. Today - 24 hours + later, injection site still itchy, swollen, red, tender and hot to the touch.